---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-072251"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:56:37.788293+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# ARCA shareholders approve merger with Oruka; 1-for-12 reverse split set for Sept 3 trading under ORKA

## Summary
- Shareholders approved all 9 proposals at Aug 22 special meeting, including merger, share increase to 545M, and reverse split.
- Board set reverse stock split ratio at 1-for-12; outstanding shares to drop from ~14.5M to ~1.21M.
- Post-merger combined company expected to have ~29.5M common shares, plus ~5.4M pre-funded warrants and ~11.4M Series B convertible shares.
- Merger expected to close Aug 29; shares to trade as Oruka Therapeutics under ticker 'ORKA' on Nasdaq Global Market starting Sept 3.
- New CUSIP 687604108 and ISIN US6876041087 assigned after reverse split; cash in lieu of fractional shares at Sept 3 closing price.

## SEC filing metadata
- accession: 0001213900-24-072251
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024072251/0001213900-24-072251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024072251/ea021219701-8k_arcabio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-072251
- JSON: https://secwatch.observer/filing/0001213900-24-072251.json
- Plain text: https://secwatch.observer/filing/0001213900-24-072251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.